Drug Insights

Is Aducanumab approved by the FDA?

15 July 2024
2 min read

Aducanumab, sold under the brand name Aduhelm, is an intravenous medication used to treat Alzheimer's disease. Aducanumab was approved by the U.S. Food and Drug Administration (FDA) on June 7, 2021. This approval is notable because Aducanumab is the first treatment approved for Alzheimer's disease that targets and reduces amyloid-beta plaques in the brain, a hallmark of the disease.

Indications and Usage

Aducanumab is indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment or at the mild dementia stage of the disease. The drug works by targeting amyloid-beta plaques in the brain, which are believed to contribute to the progression of Alzheimer's.

Administration

Aducanumab is administered as an intravenous infusion:

  • Frequency: Once every four weeks, with each infusion session lasting about an hour.
  • Dosing: The treatment begins with a titration phase, starting with lower doses and gradually increasing to the maintenance dose of 10 mg/kg every four weeks.
  • Monitoring: Patients will need regular brain MRIs to monitor for Amyloid Related Imaging Abnormalities (ARIA), a potential side effect involving brain swelling or bleeding.

Side Effects

Common side effects of Aducanumab include:

  • Headache
  • ARIA, which may present with symptoms or be detected on an MRI
  • Falls

Severe side effects may include:

  • Allergic reactions (hives, difficulty breathing, swelling)
  • Brain swelling or bleeding (dizziness, confusion, trouble walking, seizures, nausea, vision changes)

Patients should seek immediate medical attention if they experience severe side effects.

Warnings and Precautions

ARIA Risk: Aducanumab can cause ARIA, which typically resolves over time but can be serious. Symptoms include headache, dizziness, nausea, confusion, and vision changes.

Pregnancy and Breastfeeding: It is not known if Aducanumab affects an unborn baby or passes into breast milk. Patients should inform their healthcare provider if they are pregnant or planning to become pregnant.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

FDA Approves Rgenta Therapeutics' IND for RGT-61159, an Oral RNA Modulator Targeting ACC and CRC
Latest Hotspot
3 min read
FDA Approves Rgenta Therapeutics' IND for RGT-61159, an Oral RNA Modulator Targeting ACC and CRC
15 July 2024
Rgenta Therapeutics secures FDA nod for IND application of RGT-61159, an oral RNA modulator intended to stop MYB production, targeting Adenoid Cystic Carcinoma (ACC) and Colorectal Cancer (CRC).
Read →
Is Ryplazim approved by the FDA?
Drug Insights
2 min read
Is Ryplazim approved by the FDA?
15 July 2024
Ryplazim was approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021. This approval marked a significant milestone as Ryplazim is the first therapy approved for treating plasminogen deficiency type 1.
Read →
Avalo Therapeutics Announces IND Activation for AVTX-009, Targeting Hidradenitis Suppurativa Treatment
Latest Hotspot
3 min read
Avalo Therapeutics Announces IND Activation for AVTX-009, Targeting Hidradenitis Suppurativa Treatment
15 July 2024
Avalo Therapeutics Reports IND Activation for AVTX-009, an anti-IL-1β Antibody, Aimed at Treating Hidradenitis Suppurativa.
Read →
Is Brincidofovir approved by the FDA?
Drug Insights
2 min read
Is Brincidofovir approved by the FDA?
15 July 2024
Tembexa (brincidofovir) was approved by the U.S. Food and Drug Administration (FDA) on June 4, 2021.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.